Cipher Pharmaceuticals Inc. (CPHR) Posts Earnings Results, Misses Estimates By $0.01 EPS
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR) posted its quarterly earnings data on Friday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by $0.01. The business earned $9.30 million during the quarter, compared to analysts’ expectations of $10.42 million. Cipher Pharmaceuticals had a negative return on equity of 6.20% and a negative net margin of 16.09%.
Shares of Cipher Pharmaceuticals (NASDAQ:CPHR) opened at 2.92 on Monday. Cipher Pharmaceuticals has a 1-year low of $2.80 and a 1-year high of $6.37. The firm’s 50-day moving average is $3.58 and its 200-day moving average is $4.72. The company’s market cap is $76.49 million.
A number of equities research analysts have commented on CPHR shares. TD Securities restated a “buy” rating and set a $7.50 target price on shares of Cipher Pharmaceuticals in a research note on Saturday, August 13th. GMP Securities restated a “hold” rating on shares of Cipher Pharmaceuticals in a research note on Saturday, August 13th.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.
Receive News & Stock Ratings for Cipher Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.